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Abstract
Background: Different clonal types of Toxoplasma gondii are thought to be associated with distinct clinical manifestations
of infections. Serotyping is a novel technique which may allow to determine the clonal type of T. gondii humans are infected
with and to extend typing studies to larger populations which include infected but non-diseased individuals.
Methodology: A peptide-microarray test for T. gondii serotyping was established with 54 previously published synthetic
peptides, whichmimic clonaltype-specificepitopes.The test was applied to human sera (n=174) collected from individuals with
an acute T. gondii infection (n=21), a latent T. gondii infection (n=53) and from T. gondii-seropositive forest workers (n=100).
Findings: The majority (n=124; 71%) of all T. gondii seropositive human sera showed reactions against synthetic peptides
with sequences specific for clonal type II (type II peptides). Type I and type III peptides were recognized by 42% (n=73) or
16% (n=28) of the human sera, respectively, while type II–III, type I–III or type I–II peptides were recognized by 49% (n=85),
36% (n=62) or 14% (n=25) of the sera, respectively. Highest reaction intensities were observed with synthetic peptides
mimicking type II-specific epitopes. A proportion of the sera (n=22; 13%) showed no reaction with type-specific peptides.
Individuals with acute toxoplasmosis reacted with a statistically significantly higher number of peptides as compared to
individuals with latent T. gondii infection or seropositive forest workers.
Conclusions: Type II-specific reactions were overrepresented and higher in intensity in the study population, which was in
accord with genotyping studies on T. gondii oocysts previously conducted in the same area. There were also individuals
with type I- or type III-specific reactions. Well-characterized reference sera and further specific peptide markers are needed
to establish and to perform future serotyping approaches with higher resolution.
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Introduction
Infection with the intracellular protozoan parasite Toxoplasma
gondii is often asymptomatic or causes flu-like symptoms in
immunocompetent individuals. Primary maternal infection with
the parasite during pregnancy may lead to abortion or induce
disease in the transplacentally infected fetus. Toxoplasmosis is
often fatal in immunocompromised patients [1,2,3].
T. gondii has a clonal population structure. North America and
Europe are dominated by three clonal lineages of T. gondii, i.e. the
clonal types I, II and III. Type II is most abundant in infected
humans and domestic animals [4,5,6,7,8]. While type III strains
are abundant in animals, they are rarely seen in humans
[4,5,6,7,9], but this distribution may be impaired by a sampling
bias. Previous studies suggested that type I strains are relatively
rare in animals and humans and they have been predominantly
found in immunocompromised patients who had experienced a
reactivation of T. gondii infection, which frequently occurs in HIV-
infected toxoplasmosis patients [4,10]. However, Ajzenberg and
colleagues (2009) [11] demonstrated that most European immu-
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34212nocompromised patients with reactivated toxoplasmosis were
infected with T. gondii clonal type II, whereas clonal type I and
non-archetypal T. gondii types were isolated from African and
South American patients. This suggests that the occurrence of
particular T. gondii clonal types is influenced by the geographic
origin of the patients. Most T. gondii isolates obtained in South
America, Asia and Africa are genetically distinct from the clonal
types I, II and III [12,13].
T. gondii of clonal types I, II and III show different virulence
patterns in outbred mice inoculated intraperitoneally (i.p.) with
tachyzoites [14,15]. In this experimental system, T. gondii of the
clonal types II and III are characterized by LD50 values of $10
3
tachyzoites, i.e. low virulence in mice. By contrast, T. gondii isolates
of type I are highly virulent for mice with LD100 values of #10
tachyzoites [14,15]. It is not yet clear, whether these differences
also imply differences in the pathogenicity of T. gondii in humans
[15]. There is evidence, however, suggesting that host-genetic
factors also contribute to the severity of toxoplasmosis
[16,17,18,19,20,21].
Several serological assays have been reported that aim at
predicting the clonal type of T. gondii by which animals or humans
are infected [22,23,24,25,26]. Serotyping is based on the
observation that the clonal lineages of T. gondii which dominate
in North America and Europe differ not only genetically but also
in the amino acid sequences of several parasite proteins, leading to
polymorphic sites. Antibody responses against these polymorphic
sites can thus be allele-specific [22,27]. Since the three clonal types
may have arisen from common ancestors of two closely related but
genetically different lineages [8,28], many of the polymorphic sites
are specific for more than one of the three clonal types I, II or III.
The pioneering work of Kong et al. (2003) [22] showed that short
synthetic peptides derived from polymorphic regions could be used
to serologically predict the clonal type of T. gondii humans or mice
were infected with.
The aim of the present study was to test a panel of sera from T.
gondii seropositive patients and volunteers (forest workers) from
Germany against polymorphic, type-specific sites of 14 T. gondii
antigens to obtain insights into the clonal types of T. gondii these
persons were infected with and to explore potential differences in
the peptide spectra recognized by patients and seropositive but
non-diseased volunteers.
Materials and Methods
Patient sera from clinics
In total, 74 T. gondii positive human sera were provided by the
Institute of Medical Microbiology and Hospital Hygiene, Hein-
rich-Heine-University, Du ¨sseldorf and the Department of Medical
Microbiology and the National Reference Center for Systemic
Mycoses, University Medical Center, Go ¨ttingen. Out of these, 21
originated from individuals with acute toxoplasmosis, and 53 from
individuals with chronic T. gondii infection. In addition, these
institutions provided 65 samples from serologically T. gondii-
negative individuals.
Screening of human sera for T. gondii-specific immunoglobulin
G (IgG) was performed at the institutions providing the sera using
an immunofluorescence test (IFT; bioMe ´rieux, Nu ¨rtingen, Ger-
many), the LIAISON IgG immunoassay (DiaSorin, Dietzenbach,
Germany) or the Mini VIDAS immunoassay system (bioMe ´rieux
SA, Marcy l’Etoile, France). T. gondii-specific IgM was detected
using the Mini VIDAS immunoassay system (bioMe ´rieux SA,
Marcy l’Etoile, France), the LIAISON IgM immunoassay
(DiaSorin) or the ISAGA IgM immunoassay (bioMerieux).
Detailed information about the serological results for each patient
serum is shown as supporting information (Table S1). Transient
detection of T. gondii-specific IgM and eventually IgA was regarded
as an indication of an acute infection. In a few patients (n=7), a
persistent IgM response was demonstrated by repeated testing. For
these patients, a persistent but inactive (latent) infection was
assumed. Presence of IgG and absence of IgM/IgA was regarded
as an indication for persistent but inactive (latent) infection.
Sera from volunteers
A total number of 563 sera were collected from forest workers at
all forest offices in the German Federal State Brandenburg [29].
Ethical considerations
The study reported in our manuscript was a collaborative work
of the Toxonet01 project of the National Research Platform for
Zoonoses and was approved by the respective ethical committees
of the Medical Faculties of the Universities of Du ¨sseldorf (3174,
20/01/09) and Go ¨ttingen (8/6/09) and by the State Medical
Association of Brandenburg (19/04/10). Serum samples were
collected under approved protocols.
For the anonymized patient sera provided by the Institute of
Medical Microbiology and Hospital Hygiene, Heinrich-Heine-
University, Du ¨sseldorf and the Department of Medical Microbi-
ology and the National Reference Center for Systemic Mycoses,
University Medical Center, Go ¨ttingen informed consent was
obtained verbally, which was in agreement with the ethical
committee’s approval. All volunteers (forest workers) were
included in the study on the basis of written informed consent as
described in detail by Mertens et al. (2011) [29].
Latex agglutination test
A latex agglutination test (LAT, TOXOREAGENT, MAST
Diagnostica GmbH, Reinfeld, Germany) was performed accord-
ing to the instructions of the manufacturer. Results were expressed
as reciprocal antibody titres. Sera with reciprocal LAT titres of
$16 were regarded as seropositive. Reciprocal LAT titres of ,16
were considered as seronegative.
T. gondii surface antigen 1 (TgSAG1) immunoblot
Native T. gondii surface antigen 1 (TgSAG1) was affinity-purified
as previously described [30]. The identity of the purified protein
was confirmed using monoclonal antibodies against TgSAG1
(IgG2a P30/3 [ISL, Paignton, UK]). Detection of antibodies
against TgSAG1 was performed essentially as described for animal
sera [30] with a few modifications. Briefly, human sera were
diluted 1:10 and the conjugate (horse radish peroxidase [HRP]
AffiniPure rabbit anti-human IgA+IgG+IgM [H+L], Jackson
ImmunoResearch, West Grove, PA, USA) was diluted 1:500.
Reactivity with a protein of a relative molecular mass of 30 kDa
was regarded as a T. gondii positive reaction. Sera obtained from a
LAT positive and a LAT negative volunteer were used as controls.
Peptides
A total of 54 T. gondii synthetic peptides based on amino acid
sequences representing polymorphic epitopes of the three
archetypal lineages of T. gondii were used to detect type-specific
antibodies in sera of T. gondii seropositive humans from Germany.
The respective peptide sequences [22] were derived from 14 T.
gondii immunogenic proteins, including dense granule proteins,
surface antigens and rhoptry proteins (Table S2). Peptide
sequences were based on information available for representative
T. gondii strains of the clonal types I (RH), II (Me49 and
Prugniaud) and III (VEG and CEP) (previously described by Kong
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more than one of the three clonal lineages. These peptides are
referred to as type I–II, type I–III or type II–III.
Preparation of peptide-microarray slides
Peptides were synthesized and printed on peptide-microarray
slides by JPT Peptide Technologies GmbH, Berlin. First, amino-
oxy-acetylated peptides were synthesized on cellulose membranes
in parallel using the SPOT synthesis technology [31,32]. After side
chain de-protection, the solid phase-bound peptides were
transferred into 96-well microtitre filtration plates (Millipore,
Bedford, USA) and treated with 200 ml of aqueous triethylamine
(0.5% v/v) to cleave the peptides from the cellulose support.
Peptide-containing triethylamine solution was filtered off and the
solvent removed by evaporation under reduced pressure. The
resulting peptide derivatives (50 nmol) were re-dissolved in 25 ml
printing solution (70% DMSO, 25% 0.2 M sodium acetate
pH 4.5, 5% v/v glycerol) and transferred into 384-well microtitre
plates. Two droplets of 0.5 nl peptide solution (1 mM) were
deposited per spot on epoxy-functionalized glass slides (Corning
Epoxy # 40042; Corning, Lowell, USA) using the non-contact
printer Nanoplotter (GESIM, Groberkmannsdorf, Germany)
equipped with a piezoelectric NanoTip (GESIM). The method
for chemoselective immobilization on peptide-microarrays was
originally described by Panse and colleagues (2004) [33]. This
procedure was further optimized for peptide arrays for serum
antibody detection and reviewed by Andresen and Gro ¨tzinger
(2009) [34]. Chicken IgY, cat, human, mouse and pig IgG (Sigma,
Munich, Germany and Diatec, Oslo, Norway) were also printed
on the slides as antibody controls at a concentration of 500 mg/ml
in 100 mM PBS buffer, pH 8.0.
The peptide library was spotted on each slide in triplicate. The
slide layout consisted therefore of three identical sub-arrays;
peptide and control spots were printed in 21 identical blocks.
Printed peptide-microarrays were kept at room temperature for
5 h, washed with de-ionised water, quenched for 1 h with 0.1 mg/
ml bovine serum albumin (BSA) in 75 mM saline sodium citrate
(SSC) buffer, pH 7.0, containing 0.1% SDS and 750 mM NaCl, at
42uC, washed extensively with 1.5 mM SSC buffer, pH 7.0,
followed by washings with de-ionised water and dried using a chip
centrifuge (UNIEQUIP Laborgera ¨tebau und Vertriebs GmbH,
Planegg, Germany). Resulting peptide-microarrays were stored at
4uC until used.
Examination of sera by peptide-microarray
Array slides were first incubated with blocking solution (PBS,
0.05% Tween 20, 0.2% I-Block [Applied Biosystems, Bedford,
MA, USA]) for 30 min. The slides were then placed into a
Microplate Microarray Hardware (Arrayit Corporation, Sunny-
vale, CA, USA), which allows to examine arrays separately in a 96
well ELISA format.
Human serum samples (150 ml/well), diluted 1:200 in blocking
solution, were incubated at 37uC for 1 h and washed seven times
for 3 min with PBS-T (PBS, pH 7.2; 0.5% Tween 20) on a shaker
at room temperature. Conjugate (Cy5-AffiniPure donkey anti-
human IgG, Fcc fragment specific [min X Bov,Hrs,Ms Sr Prot],
Jackson ImmunoResearch Laboratories, West Grove, USA)
diluted 1:1000 (1 mg/ml) was added to the wells (150 ml/well),
incubated at 37uC for 30 min, and washed as indicated above,
followed by three additional washing steps, 1 min each, with
sterile-filtered MilliQ water. Afterwards, the slides were spun dry
for 10 s using a slide spinner (DW-41MA-230, Qualitron Inc/
Eppendorf, Berzdorf, Germany).
Scanning and measurement of spot signal intensities and
data extraction
Peptide-microarray slides were scanned at a wavelength of
635 nm using a GenePix 4000B microarray scanner (Axon
Instruments, Concord, Canada) in a low-noise, high-sensitivity
photomultiplier tube (PMT) at a level of 100% and a resolution of
10 mm. Images were saved electronically in TIFF and JPG
formats.
Image analysis was performed using the circular feature
alignment of the GenePix Pro 6.0 software (Axon Instruments)
and GenePix Array List (GAL) files. Each circular feature
consisted of the peptide spot to determine the foreground and a
surrounding area to detect the background reaction. The signals
from pixels of each circular feature were used to calculate median
net fluorescence intensities of both, the foreground and back-
ground of each peptide spot [35,36].
Peptide-microarray data analysis
To analyze the raw data (median of signal intensity) in GPR
(GenePix Results) files, index values (IVs) were recovered for each
peptide-spot as log2 of the quotient of the medians of foreground
and background [35,36]. Each serum was analyzed on a single
block with the peptides printed in triplicate in each block. To
obtain the serum-specific reaction against each peptide, the means
of the IVs for each peptide spot per block (mean sample index
value, MSIV) were calculated using the ‘‘corrected mean’’ formula
(Microsoft Office EXCEL 2003) to exclude artefacts, i.e. false-
positive and -negative signals within the replicas in each block.
Application of the ‘‘corrected mean’’ formula had the following
effect: If one out of three IVs per sample deviated more than 1.5-
fold from the mean of all three IVs, the value was discarded and
MSIV was calculated from the two remaining IVs. The peptide-
microarrays used in this study failed to meet the criteria required
for submission under MIAME based public databases [37,38].
Therefore MSIV for all sera and peptides are presented as
supporting information (Table S3).
To ensure the specificity, we established an individual cut-off for
each peptide to classify a reaction with this particular peptide as
positive or negative using receiver-operating characteristic (ROC)
analysis and the serological status of each serum (Table S3) as a
reference standard. The cut-off was selected for each peptide
separately using the MSIVs obtained for all T. gondii seronegative
and seropositive human sera and accepting a maximum of 4%
false-positive reactions. The results of ROC analysis (specificity,
area under ROC curve, sensitivity and cut-off) for each peptide are
shown as supporting information (Table S2). Table S4 shows the
results of the application of these cut-offs to the MSIV for each
serum and each peptide.
Statistical analysis
Fisher’s exact test and logistic regression were computed with R,
version 2.8.1 (R Foundation for Statistical Computing, Vienna,
Austria, ISBN 3-900051-07-0, URL http://www.R-project.org)
using packages ‘‘Stats’’ and ‘‘Epicalc’’ respectively [39]. Linear
regression and the Wilcoxon rank test were performed using
STATISTICA 8 (StatSoft, Tulsa, USA). P-values,0.05 were
regarded as statistically significant. Kappa values were calculated
using a web-based program (http://www.graphpad.com/
quickcalcs/kappa1.cfm). To adjust p-values in multiple testing
scenarios, Bonferroni correction was used [40].
To establish cut-offs for each peptide, ROC analysis was applied
using the R-package ‘‘DiagnosisMed’’.
Serotyping of Toxoplasma gondii in Humans
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log-linear independence models to examine whether reactions
with specific peptide cohorts occurred more frequently than with
others, i.e. whether the hypothesis of independence had to be
rejected. Mosaic plots were used to visualize resulting contingency
tables and Pearson residuals. Residuals displayed in mosaic plots
represent standardized deviations of observed from expected
values calculated by Pearson chi-square. The size of each box
within the plot corresponds to the observed frequencies of positive
and negative peptide reactions as well as the number of tested
peptides within a peptide cohort specific of a clonal type. To
present Pearson residuals in mosaic plots, the shading introduced
by Friendly et al. (1994) [41] was used. Blue scale shading with a
solid blue line (Pearson residuals: .2) or red scale shading with a
dashed red line (Pearson residuals: ,22) indicate statistically
significant (Pearson chi-squared p-value,0.05) over-, or under-
representation of certain clonal type-specific peptide reactions
within analyzed groups of sera, respectively (rejection of
independence hypothesis). Pearson residuals from 22 to 2 are
presented by filling the boxes in white colour, presenting the
homogeneous distribution of peptide reaction within certain
groups.
To perform multiple comparisons of the MSIVs for the tested
peptides as well as for clonal type-specific peptide groups, a Post-
Hoc-Test (LSD[Least Significant Difference]-Test) on ANOVA
results was applied using the R package ‘‘agricolae’’. The differences
between the means of positive peptide reactions in the analysis of
peptide reactivities within tested groups were regarded as
significant if the differences were equal to or higher than the
LSD values.
Results
Examination for antibodies against T. gondii in sera from
individuals and seropositive volunteers
All sera of T. gondii-infected individuals showed reciprocal LAT
titres of 16 to .2048 (Table 1; Fig. 1 [A]). The majority of sera
from individuals with an acute T. gondii infection (15 of 21; 71%)
had reciprocal LAT titres of .256, while the majority of sera from
individuals with a latent T. gondii infection (31 of 53; 59%) showed
reciprocal LAT titres of 16 to #256. All sera from seronegative
patients (n=65) had reciprocal LAT titres of ,16.
The initial LAT screening of a total of 563 sera of forest workers
revealed the presence of antibodies against T. gondii in the LAT in
476 (84%) (Table 1). The majority of these sera (351 of 476; 74%)
had LAT titres ranging between 16 and #256 (Fig. 1 [A]). The
remaining sera (n=87) were regarded as seronegative (reciprocal
LAT titres ,16). Volunteers had significantly lower LAT titres
than latently or acutely infected patients (Wilcoxon rank test, p-
value,0.001). To confirm the LAT results, all volunteer sera were
also tested by TgSAG1 immunoblot. Antibodies to TgSAG1 were
detected in 485 of 563 (86%) sera. The agreement between the
TgSAG1 immunoblot and the LAT was characterized by a kappa
value of 0.913.
Logistic regression analysis revealed that seropositivity in
volunteers (forest workers) was positively associated with age in
both the LAT and the in-house TgSAG1 immunoblot (LAT: OR
1.09 [95% CI: 1.06–1.12], pWald-value,0.001; TgSAG1 immu-
noblot: OR 1.07 [95% CI: 1.04–1.1], pWald-value,0.001).
For further examination in the peptide-microarray, 100
volunteer sera which had tested T. gondii positive in both assays
and 75 volunteer sera with negative results in both T. gondii tests
were selected randomly. Seropositive and seronegative volunteers
were interviewed during sampling to obtain information about
their health status. None of the volunteers included in this study
reported signs of acute toxoplasmosis.
Diagnostic specificity and sensitivity of peptide-
microarray testing in seronegative and seropositive sera
All sera of seronegative patients and volunteers (n=140) as well
as sera from seropositive patients and volunteers (n=174) were
used to establish peptide-specific cut-offs by ROC analysis. The
serological status of patients and volunteers was based on LAT
results as a reference standard (Table S3). Application of these cut-
offs revealed peptide-dependent diagnostic specificities for the T.
gondii-negative sera which ranged between 96% and 97% (Table
S2). A total of 174 sera, including all seropositive sera from
patients (21 with acute and 53 with latent T. gondii infection) and
100 randomly selected sera from seropositive volunteers were
tested on the peptide-microarray (Table S5). Twenty-two of these
174 (12.6%) seropositive sera failed to recognize any of the 54
peptides. All non-reactive sera had low LAT titres, i.e. showed
reciprocal LAT titres between 16 and #256.
Sera of patients with an acute T. gondii infection recognized a
significantly higher number of peptides than the sera of
seropositive volunteers (Wilcoxon Rank Test, p-value=0.012).
Also sera of patients with a latent T. gondii infection reacted with a
statistically significantly higher number of peptides than the sera of
seropositive volunteers (Wilcoxon Rank test, p-value=0.017). The
differences between individuals with acute and latent T. gondii
infections were not statistically significant (Wilcoxon rank test, p-
value=0.256). Linear regression analysis revealed that the number
Table 1. Results in the Latex-Agglutination-Test (LAT) for sera from groups of seropositive and seronegative individuals with acute
or latent toxoplasmosis including patients from clinics and volunteers (forest workers).
Group Infection status LAT titre
,16 16 32 64 128 256 512 1024 2048 .2048
Patients (n=21) Acute
* 1 1 1343 4 4
Patients (n=53) Latent
# 1171 01 23 8 1 1 0
Volunteers (n=476) Positive
V 22 44 79 111 95 76 35 9 5
Patients/Volunteers (n=152) Negative 152
*Transient detection of T. gondii specific IgM and eventually IgA was regarded as an indication of acute infection.
#Presence of IgG and absence of IgM/IgA was regarded as an indication for persistent but inactive (latent) infection. In a few patients a persistent IgM response was
demonstrated by repeated testing. For these patients, a persistent but inactive (latent) infection was assumed.
VAntibody isotypes not specified.
doi:10.1371/journal.pone.0034212.t001
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the log2-transformed reciprocal LAT titres (p-value,0.001). This
association was characterized by an R
2 value of 0.16 (Figure 1[B]).
Type-specificity of peptide reactions
In total 9396 (54 peptides6174 sera) peptide reactions were
possible: 2436 (14 peptides6174 sera) type I-specific, 2436 (14
peptides6174 sera) type II-specific, 1044 (6 peptides6174 sera)
type III-specific, 696 (4 peptides6174 sera) type I–II-, 1740 (10
peptides6174 sera) type I–III-, and 1044 (6 peptides6174 sera)
type II–III-specific. In total, 731 of 9396 (8%) possible peptide
reactions were observed. Positive reactions were predominantly
directed against type II-specific and the type II–III-specific
peptides (proportions of peptide reactions 14% [336/2436]) and
10% [106/1044], respectively). The positive reactions against type
I- (116/2436 [5%]), type III- (41/1044 [4%]), type I–II- (30/696
[4%]) or type I–III-specific (102/1740 [6%]) peptides were
underrepresented.
Reactions within clonal type-specific peptide groups were
statistically analyzed using a log-linear model. Contingency tables
and deviations from independence hypothesis were visualized in
mosaic plots (Fig. 2 [A, B, C, D]). Pearson residuals .4 indicated a
statistically significant (Chi-squared p-value,0.001) overrepresen-
tation of positive clonal type II-specific peptide reactions within all
groups of sera (Fig. 2 [A, B, C, D]). In latently infected patients,
type II–III-specific positive peptide reactions were also statistically
significantly overrepresented (Pearson residuals: 2–4; Chi-squared
p-value,0.05) (Fig. 2 [B]). In patients with an acute infection and
in volunteers reactions with type II–III-specific peptides were also
overrepresented (white rectangle with solid blue borderline),
however, the hypothesis of independence could statistically not
be rejected (Fig. 2 [A, C]). Reactions with peptides of type I, III, I–
III and I–II were underrepresented in all tested groups of sera
(Fig. 2 [A, B, C, D]).
Of 35 dense granule-derived peptides, 7 were recognized by
16%–42% of the sera (Table S5). The majority of these peptides
(n=5) had amino acid sequences specific for type II (dGRA6-II-
216(9), GRA3-II-28, GRA6-II-214, dGRA6-II-214, GRA7-II-
225; Table S5). The amino acid sequences of the remaining two
peptides were specific for both, clonal types I and III (GRA3-I/III-
28) or had a sequence specific for clonal type I (NTP3-I-99). Two
other dense granule peptides were recognized by 10–11% of the
sera. One of these peptides had a type II-specific (dGRA6-II-
214(9)) and the other peptide a type I–II-specific (GRA7-I/II-215)
amino acid sequence.
Only one of 15 surface antigen-derived (SAG3-II-49) and one of
six rhoptry-derived (ROP1-II/III-181) peptides with type II and
type II–III specificity were recognized by more than 15% of the
sera (Table S5). One rhoptry (ROP1-II/III-359) and none of the
remaining surface-derived peptides were among those recognized
by 10–15% of the sera.
Differences in intensity of type-specific peptide reactions
To detect differences between reaction intensities (MSIVs) for each
tested peptide and for peptide groups presenting clonal type
specificity in seropositive patients and volunteers, ANOVA and the
LSD-Post-Hoc-Test were performed (Fig. 3). The analyses revealed
that for the groups of acutely and latently infected patients, those
peptide groups mimicking clonal type II and II–III specificities were
recognized by the highest MSIVs as compared to the remaining
peptide groups. These differences were statistically significant
(LSD.0.36, p-value,0.05 [for acutely infected patients];
LSD.0.16, p-value,0.05 [for latently infected patients]) (Fig. 3 [A,
C]). In volunteers, the clonal type II-specific peptide group was also
recognized by the highest MSIVs as compared to remaining peptide
groups. The difference was statistically significant (LSD.0.102, p-
value,0.05 [for seropositive volunteers]) (Fig. 3 [E]).
The intensity of index values was also analysed for each peptide
in patient groups with acute or latent T. gondii infection and in
seropositive volunteers.
Peptides derived from dense granule antigens mimicking type II
specificity (GRA6-II-214, dGRA6-II-214, dGRA6-II-216(9)) and
one type II–III rhoptry derived peptide (ROP-II/III-181) were
detected by the highest MSIVs in all patient and volunteer groups.
The differences were statistically significant (LSD.0.67, p-
value,0.05 [for acutely infected patients]; LSD.0.36, p-
value,0.05 [for latently infected patients]; LSD.0.24, p-val-
ue,0.05 [for seropositive volunteers]) (Fig. 3 [B, D, F]).
Figure 1. The number of recognized peptides is associated with the titre in LAT (Latex Agglutination Test). Wilcoxon rank test analysis
of the T. gondii LAT titre distribution within groups of human sera revealed significantly lower LAT titres in sera from volunteers than in sera from
latently or in acutely infected individuals (p-value,0.001). No significant differences were observed between sera from acutely and latently infected
individuals (A). The association between LAT titre and number of recognized peptides was characterized by an R
2 value of 0.16 (p-value,0.001) (B).
doi:10.1371/journal.pone.0034212.g001
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II-specific peptides (GRA3-II-28, GRA7-II-225) were also detect-
ed by the highest MSIVs (LSD.0.67, p-value,0.05 [acutely
infected patients]; LSD.0.36, p-value,0.05 [Latently infected
patients]) (Fig. 3 [B, D]).
GRA3-I/III-28 and SRS-I-53 peptides also belong to the
peptide group recognized by the highest MSIVs in acutely T.
gondii-infected patients and in seropositive volunteers (LSD.0.67,
p-value,0.05 [acutely infected patients]; LSD.0.24, p-val-
ue,0.05 [for seropositive volunteers]) (Fig. 3 [B, F]).
Differences in number of anti-peptide reactions between
groups of sera
In all sera from patients and volunteers, reactions against type II
dense granule based peptides (GRA3-II-28, GRA6-II-214, GRA7-
II-225) and a type II–III rhoptry peptide (ROP1-II/III-181)
dominated, i.e. these peptides reacted with more than 20% of the
sera (Table S5).
In addition, further peptides were recognized by more than
20% of the sera of patients with acute toxoplasmosis (dGRA6-II-
216(9)) but not by those of seropositive volunteers and patients
with latent infection. More than 20% of the sera from patients
with latent infection recognized a type II surface antigen-derived
peptide (SAG3-II-49), but those of volunteers and individuals with
acute toxoplasmosis failed to react with this peptide in a
proportion of .20%. Two dense granule-based peptides
(dGRA6-II-214, GRA3-I/III-28) were recognized by more than
20% of the patients sera (acute, latent), but not by those of
seropositive volunteers.
No major differences within each peptide category were
observed between the different groups of persons (Table S6), with
three exceptions. Individuals with acute toxoplasmosis recognized
Figure 2. Statistically significant overrepresentation of reactions against clonal type II specific peptides. To determine whether
reactions against certain clonal type-specific peptide cohorts (I, II, III, I–II, I–III, or II–III) were over- or underrepresented in various groupso fT. gondii
positive human sera a log-linear model analysis was performed and visualized by mosaic plot: acutely infected individuals (A), latently infected
individuals (B) serologically positive volunteers (forest workers) (C) and all tested positive human sera (D). The size of each box corresponds to the
observed frequencies of positive (Pos) and negative (Neg) peptide reactions as well as the number of tested peptides within each clonal type-specific
peptide cohort. Pearson residuals represent standardized deviations of observed from expected values. The solid blue line indicates that the number
of positive or negative reactions is higher than expected but not statistically significant. Blue scale shadings suggest the statistically significant
rejection of the null hypothesis, i.e. overrepresentation of certain type-specific peptide reactions (Pearson chi-squared p-value,0.05). Dashed red
lines indicate an underrepresentation of positive or negative peptide reactions which is not statistically significant. Red scale shadings suggesta
statistically significant rejection of the null hypothesis, i.e. underrepresentation of peptide reactions within tested peptide and human groups
(Pearson chi-squared p-value,0.05).
doi:10.1371/journal.pone.0034212.g002
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sequences than volunteers (p-value=1.87610
211; Fisher’s exact
test; Table S6) and latently infected patients, (p-val-
ue=8.24610
211). Latently infected patients recognized a signif-
icantly higher proportion of peptides with type II-specific
sequences than seropositive volunteers (p-value=2.98610
25,
Fisher’s exact test; Table S6). Acutely and latently infected
patients recognized a significantly higher proportion of peptides
with type II–III specificity as compared to volunteers (p-
value=0.00021, p-value=0.0036; Fisher’s exact test; Table S6).
Peptide-microarray-based serotyping
Data analysis was carried out to identify the clonal types
responsible for the infection of the tested persons and to analyse
potential type-specific differences in the peptide spectra recognized
by individuals presenting acute or latent T. gondii infection and
seropositive volunteers.
The majority (n=124; 71%) of sera showed reactions against
synthetic peptides with sequences specific for clonal type II (type II
peptides) (Table 2). Forty-two percent (n=73) or 16% (n=28) of
the sera reacted with type I and type III peptides, respectively,
while type II–III, type I–III or I–II peptides were recognized by
49% (n=85), 36% (n=62) or 14% (n=25) sera, respectively.
Based on the anti-peptide reactions, only a fraction of sera could
be clearly attributed to either of the three clonal types I, II, or III
(Table 3). Among sera that reacted with peptides containing type
II specific sequences, 35% (50/142) showed reactions exclusively
compatible with clonal type II (Table 3). The remaining 65% (92/
142) reacted not only with type II peptides but also with peptides
with sequences specific for other clonal types. Most sera reacting
with type I and type III peptides could not be clearly assigned to
one of the three clonal lineages as many of them also recognized
peptides with sequences specific for the other clonal types (Table 3).
Discussion
A number of polymorphic peptides has been described in T.
gondii antigens which might be suitable to indirectly determine the
clonal type of T. gondii, humans or mice are infected with [22].
Using such peptides, we tested sera from seropositive volunteers
and patients from Germany, to obtain insights into the clonal types
of T. gondii by which these humans were infected and to examine
potential differences in the spectra of peptides recognized by sera
of various subgroups.
Several attempts have been made to type T. gondii infections by
serological techniques using ELISA formats in which synthetic
peptides were coupled via keyhole limpet hemocyanin [22,42] or
Figure 3. Strongest reaction intensities were recorded for clonal type II specific peptides. To evaluate the intensities (MSIVs) by which
single peptides as well as peptide cohorts (I, II, III, I–II, I–III, or II–III) were recognized by T. gondii seropositive patient and volunteer groups, ANOVA
and the Least Significant Difference (LSD)-Post-Hoc-Test were performed. Whiskers in barplots represent 95% confidence intervals of the means of
MSIVs. The differences between the means of MSIVs for single peptides or peptide cohorts within tested groups were regarded as statistically
significant, when the differences were equal or higher than the LSD values. Different letters above the whiskers indicate significant differences
between the mean intensities in the Post-Hoc-LSD test. Means of MSIVs for each peptide cohort are presented in (A) for the acutely infected patient
group (LSD.0.36, p-value,0.05); in (C) for the latently infected patient group (LSD.0.16, p-value,0.05); and in (E) for the seropositive volunteer
group (LSD.0.10, p-value,0.05). Means of MSIVs for each single peptide are presented in (B) within the acutely infected patient group (LSD.0.67, p-
value,0.05); in (D) within the latently infected patient group (LSD.0.36, p-value,0.05); and in (F) within the seropositive volunteer group
(LSD.0.24, p-value,0.05).
doi:10.1371/journal.pone.0034212.g003
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antigens for serotyping [23,26]. We applied a synthetic peptide-
microarray format to test a panel of sera simultaneously with all
peptides that had previously been used in an ELISA by Kong et al.
(2003) [22]. In studies on other infectious diseases, Melnyk et al.
(2002) [45] and Mezzasoma et al. (2002) [46] compared peptide-
ELISAs with peptide-microarrays and found that peptide-micro-
arrays were much more sensitive than peptide-ELISAs. We
therefore expected for the serological typing of T. gondii infections
that the microarray format should have at least the same sensitivity
as the previously reported ELISA format. To ensure a minimum
diagnostic specificity of 96% for each peptide, i.e. to make sure
that it is unlikely that T. gondii-negative humans react with any of
these peptides, an individual cut-off was selected for each peptide
based on the foreground-background ratio obtained for each
peptide and the sera of 140 T. gondii seronegative humans.
By conventional techniques, i.e. by PCR-RFLP mediated
genotyping using polymorphic loci, we have previously shown
that almost all T. gondii parasites isolated from cats in Germany
showed an allele combination resembling that of clonal type II
[47,48]. Only a single clonal type III isolate and a few isolates with
allele combinations different from those of clonal type I, II or III
were observed [47]. We therefore expected that the majority of
sera from seropositive humans from Germany would recognize
peptides with type II-specific amino acid sequences. This turned
out to be true since reactions with type II peptides were superior
compared to reactions with other peptides in number as well as in
intensity. Thus our results are in accord with the results of
serotyping studies performed in France and Poland with a limited
number (i.e. 8 or 2, respectively) of those 54 peptides we applied
(GRA6-II-214, GRA6-I/III-220, dGRA6-II-214, dGRAS6-I/III-
220, GRA7-II-225, GRA7-III-225, dGRA7-II-225, dGRA7-III-
225) [42,43]. In addition, our findings confirm the results of studies
from Peyron et al. (2006) and Morisset et al. (2009) with
recombinant polypeptides mimicking polymorphic clonal type-
specific sites of T. gondii GRA5 and GRA6 which revealed a
significantly dominant clonal type II-specific serological response
in patients from France, Italy and Denmark [23,26].
Although reactions with type II-specific peptides dominated in
number and intensity in our study, the sera of many of these
humans reacted also with a few peptides with sequences specific
for other clonal types. As it is unlikely that all these individuals
experienced mixed infections or infections with atypical T. gondii,
these conflicting results were probably due to the limited specificity
of some of the peptides used in serotyping. In these cases, the
clonal type of T. gondii the affected persons were infected with
could not be unambiguously determined. One reason for a low
discriminatory power of individual peptides might be the presence
of at least one further epitope in the non-polymorphic part of the
peptide in addition to the type-specific epitope in the polymorphic
site [22,23]. Therefore, our results suggest that a large panel of
well characterized human sera is needed to determine the
specificity of each polymorphic peptide. The peptides that are
finally used to differentiate clonal type-specific antibody reactions
in individuals must be selected extremely carefully. Unfortunately,
well-characterized human sera suitable for the evaluation of
peptides are rare.
The results of this study also show that the sensitivity by which
peptides were recognized varied considerably between the
examined groups of patients or volunteers, respectively. For
instance, individual type II-specific peptides were recognized by
1% to 42% of the sera.
Each individual serum recognized an almost unique spectrum of
peptides. This may reflect an individual maturation of particular
Table 2. Clonal type-specific anti-peptide reactivity of T. gondii positive humans.
Peptide specificity Acute patients (n=21) Non-acute patients (n=53)
Volunteers (forest workers)
(n=100) Total (n=174)
n% n% n% n %
I 9 43 26 49 38 38 73 42
II 19 91 38 72 67 67 124 71
III 2 10 8 15 18 18 28 16
I–II 2 10 9 17 14 14 25 14
I–III 15 71 19 36 28 28 62 36
II–III 19 91 30 57 36 3 85 49
Reactions are sorted according to the specificities of peptides.
doi:10.1371/journal.pone.0034212.t002
Table 3. Proportion of human sera showing peptide reactions compatible with T. gondii infections by clonal types I, II, or III.
Sera with anti-peptide reactions exclusively
compatible with the respective clonal type
Sera with anti-peptide reactions not exclusively
compatible with the respective clonal type
Total (%) AP (%)* LP (%)* V (%)* Total (%) AP (%)* LP (%)* V (%)*
Clonal type I 11 (11) 0 (0) 5 (15) 6 (12) 89 (89) 15 (100) 28 (85) 46 (88)
Clonal type II 50 (35) 5 (25) 16 (36) 29 (37) 92 (65) 15 (75) 28 (64) 49 (63)
Clonal type III 12 (13) 1 (6) 5 (17) 6 (13) 80 (87) 15(94) 25 (83) 40 (87)
Reactions are sorted according to their compatibility with infections of T. gondii of the clonal type I, II, or III.
*Data resolved for seropositive patients with acute toxoplasmosis (AP), patients with latent toxoplasmosis (LP) and seropositive volunteers (V).
doi:10.1371/journal.pone.0034212.t003
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produce against different antigens or epitopes of T. gondii. The
variation in the sensitivity of peptide recognition by different
groups of infected persons may be further influenced by a variety
of variables, e.g. host-genetic factors, route of infection, secondary
infections and time of primary infection [17,18,49].
We also found a statistically significant association between the
LAT titre and the number of recognized peptides, with the LAT
titres explaining 16% of the variability in the number of
recognized peptides. Consequently, groups of humans showing
differences in mean LAT titres showed similar differences in the
number of peptides recognized in the microarray analysis. For
instance, sera of patients with an acute T. gondii infection had a
significantly higher mean LAT titre (Fig. 1 [A]) and recognized a
significantly higher number of peptides than sera of seropositive
volunteers.
In this study, 13% of the LAT positive sera did not react with
any of the 54 peptides used. A previous study, in which two
ELISAs with peptides presenting clonal type II and I–III specificity
(GRA6-II-214, GRA6-I/III-220) were used, revealed that more
than 30% of seropositive sera from Europe (France and Portugal)
failed to react in these peptide ELISAs [43]. Sousa and colleagues
(2009) suggested that the use of single peptides for serotyping could
lead to mistyping. To overcome this problem, a large pool of
polymorphic peptides from different antigens should be used [24].
Although we applied a much higher number of peptides as
compared to these previous studies, we also observed a high
proportion of sera that reacted only with a low number of
peptides.
Individual peptides were only recognized by a limited number
of sera. GRA6-II-214, for example, has previously been used in a
number of other typing studies [22,24,25,41]. This peptide was
recognized only by 31% of all tested T. gondii antibody positive
sera. The truncated variations of this peptide (dGRA6-II-214;
dGRA6-II-214(9); dGRA6-II-216(9)) were recognized by even
lower proportions of T. gondii antibody-positive sera (19%, 10%
and 18%, respectively). Therefore, the results of our study show
that the sensitivity of individual peptides might be low and,
consequently, allow to conclude that serotyping with synthetic
peptides requires a large number of highly specific polymorphic
peptides.
Our results clearly showed that peptides derived from dense
granule proteins, i.e. GRA3, GRA6, and GRA7, were the most
reactive ones when tested with human sera. Of 35 dense granule-
derived peptides, 7 were recognized by more than 15% of the
examined human sera. None of the 15 surface antigen-derived
peptides and only 1 of 6 rhoptry antigen-derived peptides
rendered a similar result. This finding is in accord with the high
potential of dense granule proteins as diagnostic antigens
[50,51,52,53].
In our study, a higher proportion of acutely infected patients
recognized GRA6 and GRA3 derived peptides as compared to
individuals with latent T. gondii infection (Table S5). This is in
accord with previous results of others who showed that it is
possible to discriminate between acute and chronic T. gondii
infections by using recombinant GRA6 or GRA7 [54,55,56].
In conclusion, the results of this study demonstrate that a
peptide-microarray assay can be used to detect T. gondii clonal
type-specific antibody responses in seropositive humans. A
previous study suggested that individuals in the study area were
mainly exposed to clonal type II T. gondii [47,48]. Indeed, positive
peptide reactions presenting clonal type II specificity were
statistically significantly overrepresented in the tested human
population and the intensity by which type II peptides were
recognized was significantly higher than the intensity by which
peptides with other specificities were detected. However, to
establish serotyping assays with higher resolution, well-character-
ized reference sera and further specific peptide markers are
needed.
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